Sungho Bea/LinkedIn
Aug 2, 2025, 17:34
Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
The Heart has published on X:
“Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Apixaban was asso with a lower risk of recurrent VTE and major bleeding compared to rivaroxaban and warfarin in pts initiating oral anticoagulant therapy.”
Title: Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Authors: Sungho Bea, PharmD, PhD; Geetha S. Iyer, PhD; Dae Hyun Kim, MD, MPH, ScD; Kueiyu Joshua Lin, MD, ScD, MPH; Yichi Zhang, MS; Heidi Zakoul, BS; Helen Tesfaye, PharmD, MSc; Katsiaryna Bykov, PharmD, ScD
Read the full article here.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation